Pregled bibliografske jedinice broj: 1148982
Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target
Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target // Biomedicines, 9 (2021), 10; 1407, 12 doi:10.3390/biomedicines9101407 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1148982 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Role of Adropin in Cardiometabolic Disorders: From
Pathophysiological Mechanisms to Therapeutic Target
Autori
Božić, Joško ; Kumrić, Marko ; Tičinović Kurir, Tina ; Maleš, Ivan ; Borovac, Josip Anđelo ; Martinović, Dinko ; Vilović, Marino
Izvornik
Biomedicines (2227-9059) 9
(2021), 10;
1407, 12
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
adropin ; endothelial dysfunction ; cardiovascular disease ; pathophysiology ; biomarkers
Sažetak
Although a large amount of data supports the crucial role of endothelial dysfunction (ED) in cardiovascular diseases (CVDs), there is a large bench-to-bedside chasm between basic and clinical research of ED, limiting the implementation of these findings in everyday clinical settings. Hence, it is important to further investigate the pathophysiological mechanisms underlying ED and find modalities that will alleviate its clinical implementation. Adropin, a highly conserved peptide hormone secreted primarily by the liver, recently emerged as an important regulatory component of the vascular endothelium. Specifically, the vasoprotective role of adropin is achieved mainly by affecting endothelial NO synthesis. Thus, in this review, we aimed to summarize the current knowledge regarding the role of adropin in physiological processes and address the protective role of adropin in endothelium with consequent implications to CV pathologies. We focused on data regarding the role of adropin in the clinical setting, with concurrent implications to future clinical use of adropin. Studies suggest that plasma levels of adropin correlate with indices of ED in various pathologies and enhanced disease progression, implying that adropin may serve as a useful biomarker of ED in the upcoming future. On the other hand, despite notable results with respect to therapeutic potential of adropin in preliminary experiments, further well-designed studies are warranted in order to establish if adropin might be beneficial in this setting.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Profili:
Marino Vilović
(autor)
Marko Kumrić
(autor)
Josip Anđelo Borovac
(autor)
Tina Tičinović Kurir
(autor)
Joško Božić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus